INTRODUCTION

In 2017, the American Cancer Society estimated 28,000 new gastric cancer (GC) cases and 10,960 GC deaths to occur in the United States [1]. Due to high tumor aggressiveness, limited therapeutic options and late diagnosis, GC remains the third leading cause of cancer-related death globally [2]. Risk factors associated with GC include infection with Helicobacter pylori and Epstein-Barr virus, and family history of GC [3]. Dysregulation of oncogenes and tumor suppressor genes plays a crucial role in the progression of GC [4], however, the underlying mechanisms are largely unknown.

Noncoding RNAs represent a significant portion of the human genome and include, among others, microRNAs (miRNAs), long noncoding RNAs (lncRNAs), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs) [5]. LncRNAs are transcripts longer than 200 nucleotides that have an important role in transcriptional and posttranscriptional regulation of gene expression. These ncRNAs are implicated in various physiological and pathological processes, including inflammation, development, neurodegenerative and cardiovascular diseases [6]. In cancer, aberrantly expressed lncRNAs lead to epigenetic and transcriptional changes of cancer-related genes, which suggests they could be used as diagnostic and prognostic markers, as well as therapeutic targets [7,8]. For example, Liang et al. showed that H19 lncRNA accelerates tumor growth in colorectal cancer (CRC) and promotes epithelial to mesenchymal transition (EMT), by competitively binding to miR-200a and miR-138 and upregulating the expression of vimentin, zinc finger E-box binding homeobox 1 (ZEB1) and ZEB2 [9]. Increased expression of lncRNA plasmacytoma variant translocation 1 (PVT1) in pancreatic ductal adenocarcinoma (PDAC) is associated with clinical stage, N-classification, and poor overall survival (OS) [10]. Enhanced expression of lncRNA-activated...
by transforming growth factor beta [TGF-β] (lncRNA-ATB) predicts poor prognosis and promotes metastasis in colon cancer by repressing E-cadherin expression [11].

LncRNAs associated with GC include homeobox A11 antisense (HOX11-AS) [12], maternally expressed 3 (MEG3) [13], HOX transcript antisense RNA (HOTAIR) [14], and growth arrest-specific 5 (GAS5) [15].

MNX1 antisense RNA 1 (MNX1-AS1) is a lncRNA located on chromosome 7. In patients with ovarian cancer, MNX1-AS1 expression is associated with the International Federation of Gynecology and Obstetrics (FIGO) stage, tumor grade, distant metastasis and poor OS, which suggests it could be used as a prognostic marker [16]. Moreover, downregulation of MNX1-AS1 by RNA interference suppresses cell proliferation, colony formation, cell migration ability and promotes apoptosis in ovarian cancer cell lines, indicating that MNX1-AS1 has an oncogenic role in ovarian cancer [17]. Similarly, Gao et al. [18] showed that MNX-AS1 promotes glioblastoma cell proliferation, invasion and migration, by suppressing miR-4443. However, the biological function and clinicopathological significance of MNX1-AS1 in GC remain unclear.

In this study, we first analyzed the expression of MNX1-AS1 in GC and adjacent non-tumor tissues in relation to clinicopathological features and 5-year OS of GC patients. Next, we assessed MNX1-AS1 expression in five human GC cell lines compared to a normal gastric epithelial cell line. Finally, we performed loss-of-function experiments in two GC cell lines using RNA interference, to investigate the effect of MNX1-AS1 on GC cell proliferation, migration and invasion. This study provides novel findings on the diagnosis and treatment of GC.

### MATERIALS AND METHODS

#### Patients and tissue samples

A total of 96 primary GC and adjacent non-tumor tissues (>3 cm away from the tumor margin) were collected from patients diagnosed with GC by pathology at the Affiliated Hospital of Jining Medical University. All tissue samples were immediately frozen in liquid nitrogen and stored at -80 °C until analysis. None of the patients had received preoperative radiotherapy or chemotherapy. Follow-up data and written informed consent were obtained for all patients. Clinicopathological data, including gender, age, tumor-node-metastasis (TNM) staging and tumor size, were recorded and are summarized in Table 1. OS was defined as the time from the date of primary surgery to the date of death or to the end of follow-up. This study was approved by the ethical committees of Affiliated Hospital of Jining Medical University.

#### Cell culture and transfection

Five human GC cell lines (MKN-45, SGC-7901, AGS, MGC-803, and BGC-823) and one normal gastric epithelial cell line (GES-1) were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). MKN-45, MGC-803, BGC-823, and GES-1 cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS). SGC-7901 and AGS cells were cultured in DMEM (Gibco) with 10% FBS. All cells were maintained at 37 °C, under an atmosphere containing 5% CO₂.

| TABLE 1. Association between MNX1-AS1 expression and clinicopathological characteristics of patients with gastric cancer |
|---------------------------------------------------------------|
| Characteristics                                 | Cases (n=96) | MNX1-AS1 expression | p      |
| Age                                           |              | Low (n=48) | High (n=48) | Chi-square test |
| ≤50                                          | 40           | 17         | 23         | 0.546           |
| >50                                          | 56           | 31         | 25         |                 |
| Gender                                       |              |            |            | 0.729           |
| Male                                         | 54           | 25         | 29         |                 |
| Female                                       | 42           | 23         | 19         |                 |
| Tumor size (cm)                              |              |            |            | 0.012           |
| <5.0                                         | 50           | 35         | 15         |                 |
| ≥5.0                                         | 46           | 13         | 33         |                 |
| TNM stage                                    |              |            |            | 0.003           |
| I/II                                         | 40           | 35         | 5          |                 |
| III/IV                                       | 56           | 13         | 43         |                 |
| Lymph node metastasis                       |              |            |            | 0.018           |
| Negative                                     | 52           | 35         | 17         |                 |
| Positive                                     | 44           | 13         | 31         |                 |
| Pathological differentiation                |              |            |            | 0.273           |
| Well/moderate                                | 29           | 12         | 17         |                 |
| Poor                                         | 67           | 36         | 31         |                 |

TNM: tumor-node-metastasis; MNX1-AS1: MNX1 antisense RNA 1
Small interfering RNA (siRNA) targeting MNX1-AS1 (si-MNX1-AS1) and non-targeting negative control siRNA (si-NC) were purchased from Ribobio Co., Ltd. (Guangzhou, China). For transfection experiments, AGS and MGC-803 cells were seeded in 6-well plates and cultured to reach 80% confluence. The cells were transfected with si-MNX1-AS1 or si-NC using RNAiMAX (Invitrogen, Shanghai, China) according to the manufacturer's instructions. Forty-eight hours after transfection, the cells were harvested for subsequent experiments.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Total RNA was extracted from tissue samples or cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and complementary DNA (cDNA) was synthesized from isolated RNA using PrimeScript RT Kit (TaKaRa, Dalian, China), according to the manufacturer’s instructions. qRT-PCR was performed on an ABI 7500 system (Applied Biosystems, Foster City, CA, USA) using SYBR Premix Ex Taq (TaKaRa, Dalian, China). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was the internal control. The following primers were used: MNX1-AS1 forward 5'-CCCGCATT TTCAGATTCAC-3’, reverse 5'-GCTCTCAG CCTCGCCATA-3'; GAPDH forward 5'-GCACCGTCAA GGCTGAGAA-3’, reverse 5'-GTGAAGACGCCA GTGGACTC-3’. Each sample was analyzed in triplicate. The relative expression of MNX1-AS1 was normalized to GAPDH mRNA by the 2-ΔΔCt method.

Cell proliferation assay

Cell proliferation was analyzed by Cell Counting Kit-8 (CCK-8) assay (Beyotime Institute of Biotechnology, Shanghai, China), according to the manufacturer’s instructions. Briefly, around 3,000 transfected cells were seeded in a 96-well plate and cultured overnight. CCK-8 solution was added to the wells at 24, 48, 72 or 96 hours of incubation and the cells were incubated for another 2 hours at 37 °C. The absorbance value (OD) of each well was measured at 450 nm on a microplate reader. The experiments were independently performed three times.

Cell migration and invasion assays

Cell migration and invasion assays were performed using 24-well Transwell chambers with 8 μm pore size (BD Biosciences). For migration assay, approximately 1×10³ of transfected cells were seeded into the upper chamber (with a permeable membrane) in serum-free medium and incubated for 24 hours. A medium containing 10% FBS, which serves as a chemoattractant, was added to the lower chamber. After 24 hours of incubation, cells that migrated to the bottom of the membrane were fixed with 4% formaldehyde for 10 minutes and stained with 0.5% crystal violet solution. The stained cells were observed and counted under a microscope (Olympus Corp., Tokyo, Japan) at 200× magnification. The protocol was identical for cell invasion assay, except that the upper chambers were precoated with 40 μl of diluted Matrigel (BD Biosciences).

Western blot analysis

Total protein was extracted from cells using RIPA lysis buffer (Beyotime, Beijing, China) and protein concentration was determined using a BCA protein assay kit (Beyotime, Beijing, China). Subsequently, 30 μg of protein was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% skim milk and incubated with primary antibodies against proliferating cell nuclear antigen (PCNA), E-cadherin, N-cadherin, vimentin, matrix metalloproteinase 9 (MMP-9), and GAPDH as a control (all from Abcam, Cambridge, UK). After washed with phosphate buffered saline (PBS) with Tween 20 for 25 minutes (5 times × 5 minutes), the membrane was incubated with goat anti-rabbit horseradish peroxidase (HRP)-conjugated polyclonal secondary antibody, followed by signal detection with enhanced chemiluminescence detection kit (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).

Statistical analysis

Statistical analysis was performed using SPSS Statistics for Windows, Version 17.0. (SPSS Inc., Chicago, IL, USA). Ninety-six GC tissues were divided into groups with high and low expression, according to the median expression levels of MNX1-AS1. The association between MNX1-AS1 expression and clinicopathological characteristics of GC patients was analyzed using the chi-square test. The OS of GC patients was estimated by the Kaplan–Meier method and compared between the groups with low and high MNX1-AS1 expression using the log-rank test. In vitro experiments were performed in triplicate and quantitative data are expressed as mean ± standard deviation (SD). Two-tailed Student’s t-test was used to determine significant differences between si-MNX1-AS1 and si-NC groups. A p-value <0.05 was considered statistically significant.

RESULTS

Clinicopathological significance of MNX1-AS1 expression in GC

To investigate the clinicopathological significance of MNX1-AS1 in GC, we analyzed MNX1-AS1 expression in
167

Wei Zhang, et al.: Clinicopathological significance and function of MNX1-AS1 in GC

We found that MNX1-AS1 expression was higher in GC compared to adjacent normal tissues (Figure 1A, p < 0.001). Next, we analyzed the association between MNX1-AS1 expression and the clinicopathological characteristics of GC patients. According to the median expression levels of MNX1-AS1, GC tissues were divided into low expression group (n = 48) and high expression group (n = 48). As shown in Table 1, higher MNX1-AS1 expression was significantly associated with tumor size (p = 0.012), TNM stage (p = 0.003) and lymph node metastasis (p = 0.018). On the other hand, no significant association was observed between MNX1-AS1 expression and age, gender and pathological differentiation (all p > 0.05).

High MNX1-AS1 expression is associated with poor prognosis in GC patients

We further explored the prognostic value of MNX1-AS1 in GC. Kaplan–Meier survival analysis with log-rank test was used to analyze the association between MNX1-AS1 expression and patient OS. As shown in Figure 1B, GC patients with high MNX1-AS1 expression had a poorer 5-year OS compared to those with low MNX1-AS1 expression (p = 0.0036). The univariate analysis (Table 2) showed that the tumor size (HR: 2.013, 95% CI: 1.536–2.856, p = 0.010), TNM stage (HR: 1.360, 95% CI: 0.898–2.325, p = 0.203), lymph node metastasis (HR: 3.756, 95% CI: 2.345–4.285, p = 0.003) and MNX1-AS1 expression (HR: 3.114, 95% CI: 2.035–4.123, p = 0.001) were prognostic factors for OS in GC patients. Furthermore, the multivariate analysis (Table 2) confirmed that high MNX1-AS1 expression (HR: 2.375, 95% CI: 1.839–3.236, p = 0.004) is a poor prognostic factor in GC patients independent of TNM stage (HR: 2.041, 95% CI: 1.762–2.359, p = 0.022) and lymph node metastasis (HR: 2.784, 95% CI: 1.945–3.596, p = 0.032).

MNX1-AS1 knockdown inhibited proliferation, migration and invasion of GC cells

Since MNX1-AS1 expression was higher in GC vs. normal tissues, we speculated that MNX1-AS1 might have an oncogenic role in GC. To validate our hypothesis, we assessed the expression of MNX1-AS1 in five human GC cell lines and the normal gastric cell line GES-1, using qRT-PCR. As shown in Figure 2A, MNX1-AS1 expression was higher in all five GC cell lines (MKN-45, SGC-7901, AGS, MGC-803, and BGC-823) compared to GES-1 cells (p < 0.01 or p < 0.001). Because MNX1-AS1 expression was relatively higher in AGS and MGC-803 compared to the other three GC cell lines, we selected AGS and MGC-803 cell lines for loss-of-function experiments. The qRT-PCR analysis confirmed that the transfection of AGS and MGC-803 cell lines with si-MNX1-AS1 knockdown MNX1-AS1 expression in these cells (Figure 2B, p < 0.001). The CCK-8 assay showed that

TABLE 2. Univariate and multivariate Cox regression analysis of factors influencing overall survival in gastric cancer patients

| Variables                        | HR     | 95% CI       | p    |
|----------------------------------|--------|--------------|------|
| **Univariate analysis**          |        |              |      |
| Age                              | 0.875  | 0.765–1.132  | 0.563|
| Gender                           | 0.756  | 0.615–1.352  | 0.853|
| Tumor size (cm)                  | 2.013  | 1.536–2.856  | 0.010|
| TNM stage                        | 1.560  | 0.898–2.325  | 0.023|
| Lymph node metastasis            | 3.756  | 2.345–4.285  | 0.003|
| Pathological differentiation     | 1.123  | 0.812–1.745  | 0.526|
| MNX1-AS1 expression              | 3.114  | 2.035–4.123  | 0.001|
| **Multivariate analysis**        |        |              |      |
| Tumor size (cm)                  | 1.574  | 1.123–2.589  | 0.051|
| TNM stage                        | 2.041  | 1.762–3.359  | 0.022|
| Lymph node metastasis            | 2.784  | 1.945–3.596  | 0.032|
| MNX1-AS1 expression              | 3.275  | 1.809–3.236  | 0.001|

TNM: tumor-node-metastasis, MNX1-AS1: MNX1 antisense RNA 1

FIGURE 1. MNX1 antisense RNA 1 (MNX1-AS1) expression is related to poor prognosis of gastric cancer patients. A) Expression of MNX1-AS1 in 96 paired gastric cancer (GC) and adjacent normal tissues was analyzed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Relative MNX1-AS1 expression was higher in GC compared to adjacent normal tissues (p < 0.001). B) GC tissues were divided into low expression group (n = 48) and high expression group (n = 48), according to the median expression levels of MNX1-AS1. Kaplan–Meier survival analysis with log-rank test was used to evaluate the association between MNX1-AS1 expression and patient overall survival (OS). GC patients with high MNX1-AS1 expression had a poorer 5-year OS compared to those with low MNX1-AS1 expression (p = 0.0036).
MNX1-AS1 knockdown significantly impaired proliferation of AGS (Figure 2C, \(p < 0.001\)) and MGC-803 cells (Figure 2D, \(p < 0.001\)).

In addition, we analyzed the effects of MNX1-AS1 knockdown on GC cell migration and invasion ability. The Transwell migration assay showed that the number of migrated AGS
and MGC-803 cells was markedly decreased in si-MNX1-AS1 compared to si-NC group (Figure 3A, \( p < 0.001 \)). Consistently, the Matrigel invasion assay demonstrated that MNX1-AS1 knockdown inhibited the invasion ability of AGS and MGC-803 cells (Figure 3B, \( p < 0.01 \) and \( p < 0.001 \) compared to si-NC, respectively). These results together indicated that MNX1-AS1 plays a positive role in GC cell proliferation and metastasis.

**Mechanism of MNX1-AS1 in GC cell proliferation and migration**

To further elucidate the molecular mechanisms underlying MNX1-AS1 control of GC cell proliferation and migration, we assessed the effects of MNX1-AS1 knockdown on the expression of related proteins. The Western blot analysis showed that MNX1-AS1 knockdown decreased the expression of proteins involved in cell proliferation (PCNA), EMT (N-cadherin and vimentin) and metastasis (MMP-9), and upregulated E-cadherin expression in both AGS (Figure 4A) and MGC-803 (Figure 4B) cell lines, compared to the corresponding si-NC controls. These results indicated that MNX1-AS1 regulates proliferation, migration and invasion of GC cells at least partially through PCNA and the EMT pathway.

**DISCUSSION**

LncRNAs are implicated in different pathophysiological processes and are considered to be promising diagnostic/prognostic markers and therapeutic targets. In recent years, considerable effort has been made to identify mechanisms of lncRNAs in cancer initiation and progression [19]. Previous studies suggested that MNX1-AS1 lncRNA has an oncogenic role in ovarian cancer [17] and glioblastoma [18], however, the biological function and clinicopathological significance of MNX1-AS1 in GC have not been systematically investigated so far. In this study, we analyzed the expression of MNX1-AS1 in GC and adjacent non-tumor tissues in relation to clinicopathological features and 5-year OS of GC patients. Furthermore, we conducted loss-of-function experiments to investigate the

![Figure 4](image.png)

**FIGURE 4.** Mechanism of MNX1-AS1 in proliferation and migration of gastric cancer (GC) cells. AGS and MGC-803 cells were transfected with si-MNX1-AS1 or si-NC. Western blot was performed to analyze the expression of PCNA, E-cadherin, N-cadherin, vimentin and MMP-9 in A) AGS and B) MGC-803 cells. GAPDH was used as the internal control. MNX1-AS1 knockdown decreased the expression of proteins involved in cell proliferation (PCNA), EMT (N-cadherin and vimentin), and metastasis (MMP-9), and upregulated E-cadherin expression in both AGS and MGC-803 cells. Quantitative data are expressed as mean ± standard deviation (SD). *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \) vs. si-NC. MNX1-AS1: MNX1 antisense RNA 1; si-MNX1-AS1: Small interfering RNA (siRNA) targeting MNX1-AS1; si-NC: Non-targeting negative control siRNA; PCNA: Proliferating cell nuclear antigen; MMP-9: Matrix metallopeptidase 9; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; EMT: Epithelial to mesenchymal transition.
function and mechanism of MNX1-AS1 in GC. We showed that MNX1-AS1 expression was higher in GC compared to adjacent normal tissues. High MNX1-AS1 expression in GC patients was significantly associated with tumor size, TNM stage and lymph node metastasis and, according to multivariate analysis, it was an independent predictor of survival in GC. The in vitro analysis showed that MNX1-AS1 expression was higher in GC cell lines MKN-45, SGC-7901, AGS, MGC-803, and BGC-823 compared to normal gastric cell line GES-1. The knockdown of MNX1-AS1 expression in AGS and MGC-803 cell lines significantly inhibited cell proliferation, migration and invasion, indicating that MNX1-AS1 has an oncogenic function in GC.

Carcinogenesis is a complex and multistage process characterized by uncontrolled cell proliferation [20]. Changes in the expression of proteins involved in DNA replication, DNA repair and cell cycle progression, such as PCNA, are associated with tumor growth and progression [21]. As a non-histone nuclear protein, PCNA (36 kDa) is synthesized before the S-phase of the cell cycle and functions as a cofactor of DNA polymerase δ and ε during DNA replication [22]. Expression of PCNA and two other proliferative markers, Ki-67 and minichromosome maintenance complex component 2 (MCM-2), in pT3, G2 CRC is associated with development of lymph node metastasis [23]. Conversely, reduced expression of PCNA and Ki-67 is at least partially related to decreased proliferation of CRC cells [24]. In lung adenocarcinoma, miR-363-3p impairs cell proliferation by targeting PCNA [21]. A clinical study showed higher survival rates in patients with anorectal malignant melanoma who have lower PCNA scores compared to those with higher PCNA scores [25]. The association between high PCNA expression and poor survival was also observed in GC [26], oral squamous cell carcinomas [27], and cervical cancer [28] among others. In our study, PCNA expression in MNX1-AS1-silenced AGS and MGC-803 GC cells was decreased compared to si-NC control cells, suggesting that the reduction in PCNA expression contributed to the decreased proliferation of GC cells. We hypothesize that the positive regulation of PCNA by MNX1-AS1 is one of the mechanisms underlying the significant association of high MNX1-AS1 expression with tumor size, TNM stage, lymph node metastasis, and poor survival in GC patients.

The EMT, a biological process in which epithelial cells transform into mesenchymal cells, is considered to be a major mechanism of carcinogenesis, leading to increased cell migration, acquisition of invasiveness and metastasis [29,30]. The EMT markers E-cadherin, N-cadherin, and vimentin were found to be prognostic in GC [31-33]. Transcriptional downregulation of the cell adhesion protein E-cadherin leads to the loss of cell-cell contact thus enabling cancer cells to acquire migratory and invasive abilities [34]. On the other hand, N-cadherin, a calcium-dependent cell adhesion molecule that mediates epithelial-mesenchymal cell interactions, and the intermediate filament protein vimentin are upregulated during the EMT of cancer cells [35]. Furthermore, to escape the primary tumor and migrate to new locations cancer cells utilize proteolytic enzymes such as MMPs to degrade the extracellular matrix (ECM) [36]. In the present study, si-MNX1-AS1-transfected GC cells exhibited increased E-cadherin, and decreased N-cadherin, vimentin and MMP-9 protein expression compared to si-NC-transfected cells. These results indicate that the knockdown of MNX1-AS1 inhibited the EMT and degradation of the ECM in GC cells and therefore suppressed their migration and invasion. This may be another mechanism explaining the observed association between high MNX1-AS1 expression and clinicopathological characteristics and prognosis of GC patients.

The limitations of our study are as follows: 1) the function of MNX1-AS1 was not investigated in in vivo animal models; 2) the activity of MMP-9 in GC cells should be further confirmed using Gelatin zymography; 3) a larger number of GC tissue samples should be analyzed to confirm the expression of PCNA, E-cadherin, N-cadherin, vimentin and MMP-9 in relation to MNX1-AS1.

CONCLUSION

In summary, we showed that high MNX1-AS1 expression is associated with tumor size, TNM stage, and lymph node metastasis in GC. It appears that MNX1-AS1 is implicated in GC cell proliferation, invasion and migration through the regulation of PCNA, EMT-related markers and MMP-9. Characterization of MNX1-AS1 function in GC should enable a better understanding of its role in human cancer.

DECLARATION OF INTERESTS

The authors declare no conflict of interests.

REFERENCES

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30. https://doi.org/10.3322/caac.21387.
[2] Patru CL, Surlin V, Georgescu I, Patru E. Current issues in gastric cancer epidemiology. Rev Med Chir Soc Med Nat Iasi 2013;117(1):199-204.
[3] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202-9. https://doi.org/10.1038/nature13480.
[4] Kulasekararaj AG, Kosmidis O, Mufti GJ. Diagnosis and Prognosis: Molecular. In: Platzbecker U, Fenaux P, editors. Myelodysplastic Syndromes: Diagnosis - Prognosis - Therapy. Cham: Springer International Publishing; 2018. p. 15-37. https://doi.org/10.1007/978-3-319-76879-3_2.
Fatica A, Bozzi M. Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet 2014;15(1):7-21. 
https://doi.org/10.1038/nrg3606.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12(12):801-7. 
https://doi.org/10.1038/nrg3074.

Ferreira HJ, Esteller M. Non-coding RNAs, epigenetics, and cancer: Tying it all together. Cancer Metastasis Rev 2018;37(1):55-73. 
https://doi.org/10.1007/s10555-017-9715-8.

Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell 2016;29(4):452-63. 
https://doi.org/10.1016/j.ccell.2015.10.018.

Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget 2015;6(26):22533-25. 
https://doi.org/10.18632/oncotarget.5145.

Huang C, Yu W, Wang Q, Cui H, Wang Y, Zhang L, et al. Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med 2015;106(3):143-9.

Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol 2016;31(3):595-603. 
https://doi.org/10.1111/1440-1758.13066.

Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, et al. LncRNA HOTAIR promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNM1. Cancer Res 2016;76(21):6299-310. 
https://doi.org/10.1158/0008-5472.CAN-16-0356.

Peng W, Si S, Zhang Q, Liu C, Zhao F, Wang F, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res 2015;34:79. 
https://doi.org/10.1186/s13046-015-0197-7.

Pan W, Liu L, Wei J, Ge Y, Zhang J, Chen H, et al. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility. Mol Cancer 2016;15(3):90-6. 
https://doi.org/10.1002/mc.22261.

Sun M, Jin FY, Xia R, Kong R, Li JH, Yu TP, et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 2014;14:319. 
https://doi.org/10.1186/1471-2407-14-319.

Li AH, Zhang HH. Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci 2017;21(4):659-63. 
https://doi.org/10.1186/s12859-016-1400-3.

Lv Y, Li H, Li F, Liu P, Zhao X. Long noncoding RNA MNX1-AS1 knockdown inhibits cell proliferation and migration in ovarian cancer. Cancer Biother Radiopharm 2017;32(3):291-9. 
https://doi.org/10.1089/cbr.2017.2787.

Gao Y, Yu Y, Wang J, Yang X, Wen L, Feng J. LncRNA MNX1-AS1 promotes glioblastoma progression through inhibition of miR-4443. Oncol Rep 2018. [Epub ahead of print]. 
https://doi.org/10.3747/018583818X15229609735079.

Liu Y, Zeng X, He Z, Zou Q. Inferring microRNA-disease associations by random walk on a heterogeneous network with multiple data sources. IEEE/ACM Trans Comput Biol Bioinform 2017;14(4):905-15. 
https://doi.org/10.1109/TCBB.2016.2550342.

Smith MT, Guyton KZ, Gibbons CE, Fritz JM, Portier CJ, Rusyn I, et al. Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ Health Perspect 2006;114(6):713-21. 
https://doi.org/10.1289/ehp.8909992.

Wang Y, Chen T, Huang H, Jiang Y, Yang L, Lin Z, et al. miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma. Oncotarget 2017;8(12):20333-44. 
https://doi.org/10.18632/oncotarget.15448.

Stralka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Ann Bot 2011;107(1):117-20. 
https://doi.org/10.1093/aob/mcr023.

Guzinska-Ustymowicz K, Puczynicz A, Kemona A, Czyzewska J. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bel-2 in colorectal cancer. Anticancer Res 2009;29(8):3049-52.

Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett 1997;115(2):229-34. 
https://doi.org/10.1016/S0304-3835(97)00470-X.

Ben-Zdhak O, Bar-Chama M, Sussman L, Dubiner V, Sandbank J, Cagnano M, et al. K67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002;41(6):539-53. 
https://doi.org/10.1046/j.1365-3259.2002.01444.x.

Lee KE, Lee HJ, Kim YH, Yu HI, Yang HK, Kim WH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33(4):173-9. 
https://doi.org/10.1038/jjco.03093.

Mestrinho LA, Fasca P, Peleiterio MC, Niza MM. PCNA and grade in 13 canine oral squamous cell carcinomas: Association with prognosis. Vet Comp Oncol 2017;15(1):18-24. 
https://doi.org/10.1111/vco.12144.

Lv Q, Zhang J, Yi Y, Huang Y, Wang Y, Wang Y, et al. Proliferating cell nuclear antigen has an association with prognosis and risks factors of cancer patients: A systematic review. Mol Neurobiol 2016;53(9):6209-17. 
https://doi.org/10.1007/s12035-015-9525-3.

Kahari V, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119(6):1420-8. 
https://doi.org/10.1172/JCI19101.

Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527(7579):525-30. 
https://doi.org/10.1038/nature16064.

Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, et al. Osteopontin, E-cadherin, and beta-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer 2016;19(2):412-20. 
https://doi.org/10.1007/s10120-015-0495-y.

Jun KH, Lee JE, Kim SH, Jung JH, Choi HK, Kim YL, et al. Clinopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncol Rep 2015;34(4):2047-53. 
https://doi.org/10.3892/or.2015.4191.

Otsuki S, Inokuchi M, Enjoji M, Ishikawa T, Kato K, et al. Vimentin expression is associated with decreased survival in gastric cancer. Oncol Rep 2011;25(2):1235-42. 
https://doi.org/10.3892/or.2011.1185.

Yilmaz M, Christofori G, EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28(1-2):15-33. 
https://doi.org/10.1007/s10555-008-9169-0.

Richardson AM, Havel IS, Koven AE, Konen JM, Shupe J, Hilliard GM, et al. Macrophage-secreted TNFα and TGFβ1 influence migration speed and persistence of cancer cells in 3D tissue culture via independent pathways. Cancer Res 2017;77(7):2137-90. 
https://doi.org/10.1158/0008-5472.CAN-16-0442.